Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 nov. 2025 08h30 HE | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity

Woburn, MA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two...
10 nov. 2025 08h30 HE | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Names Ogilvy Health as PR and Marketing Agency of Record to Drive Strategic Brand Repositioning and Enhance Market Visibility

New York, NY and Woburn, MA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals names Ogilvy Health as public relations and marketing agency of record. Ogilvy Health's mandate will focus on...
24 oct. 2025 11h51 HE | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution

Woburn, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin™ (clonidine hydrochloride) oral...
17 oct. 2025 11h53 HE | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces the FDA Approval of Ferabright<sup>TM</sup> (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain

Woburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the...